Drug details

Verquvo (vericiguat tablets)

type of Soluble Guanylate Cyclase Stimulators

Verquvo (vericiguat) is a soluble guanylate cyclase (sGC) stimulator, indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.

The drug is often used to treat Heart failure .

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• pale skin,
• lightheadedness,
• unusual tiredness,
• shortness of breath, and
• cold hands and feet

The following drugs are related to Verquvo, either as a replacement or used together:

• Accupril (quinapril hydrochloride)
• Aceon (perindopril erbumine)
• Aldactone (spironolactone)
• Altace (ramipril tablets)
• Altace Capsules (ramipril capsules)
• Atacand (candesartan cilexetil)
• Atacand HCT (candesartan cilexetil-hydrochlorothiazide)
• Zebeta (bisoprolol fumarate)
• Capoten (captopril)
• Coreg (carvedilol)
• Coreg CR (carvedilol phosphate extended-release)
• Corlanor (ivabradine tablets)
• Cozaar (losartan potassium)
• Demadex (torsemide)
• Diovan (valsartan)
• Diovan HCT (valsartan and hydrochlorothiazide)
• Dutoprol (metroprolol)
• Dyrenium (triamterene)
• Vasotec (enalapril)
• Inspra (eplerenone)
• Monopril (fosinopril sodium)
• Monopril HCT (fosinopril sodium-hydrochlorothiazide tablets)
• Lozol (indapamide)
• Prinivil (lisinopril)
• Zestril (lisinopril)
• Mavik (trandolapril)
• Zaroxolyn (metolazone tablets)
• Toprol XL (metoprolol succinate)